BCG treatment for bladder cancer, from past to present use

Jason Alcorn, Rob Burton, Annie Topping

    Research output: Contribution to journalArticle

    Abstract

    Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) has been in and out of favour. However, only a small proportion of patients, as low as 16%, complete what is seen as a gold standard treatment. To understand why it is the gold standard treatment the epidemiology and aetiology of NMIBC is presented. This article discusses how BCG was first discovered in cows to it being used as a treatment for NMIBC. The issues of side effects which can be from mild to severe and local to systemic, will be discussed. The impact of age in the tolerance of this treatment will be also be looked at. In conclusion, with BCG treatment being the preferred option for NMIBC, it also comes with significant side effects. It is these that should be of concern to the health care professional as they can be potentially life threatening.

    LanguageEnglish
    Pages177-186
    Number of pages10
    JournalInternational Journal of Urological Nursing
    Volume9
    Issue number3
    DOIs
    Publication statusPublished - 1 Nov 2015

    Fingerprint

    Mycobacterium bovis
    Urinary Bladder Neoplasms
    Therapeutics
    Epidemiology
    Delivery of Health Care

    Cite this

    Alcorn, Jason ; Burton, Rob ; Topping, Annie. / BCG treatment for bladder cancer, from past to present use. In: International Journal of Urological Nursing. 2015 ; Vol. 9, No. 3. pp. 177-186.
    @article{7c6741e8eb824194950fe51a3ca5ad5b,
    title = "BCG treatment for bladder cancer, from past to present use",
    abstract = "Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) has been in and out of favour. However, only a small proportion of patients, as low as 16{\%}, complete what is seen as a gold standard treatment. To understand why it is the gold standard treatment the epidemiology and aetiology of NMIBC is presented. This article discusses how BCG was first discovered in cows to it being used as a treatment for NMIBC. The issues of side effects which can be from mild to severe and local to systemic, will be discussed. The impact of age in the tolerance of this treatment will be also be looked at. In conclusion, with BCG treatment being the preferred option for NMIBC, it also comes with significant side effects. It is these that should be of concern to the health care professional as they can be potentially life threatening.",
    keywords = "Bacillus Calmette-Guerin, Bladder, Carcinoma, Immunotherapy, Intravesical therapy, Non-muscle-invasive bladder cancer",
    author = "Jason Alcorn and Rob Burton and Annie Topping",
    year = "2015",
    month = "11",
    day = "1",
    doi = "10.1111/ijun.12064",
    language = "English",
    volume = "9",
    pages = "177--186",
    journal = "International Journal of Urological Nursing",
    issn = "1749-7701",
    publisher = "Wiley-Blackwell",
    number = "3",

    }

    BCG treatment for bladder cancer, from past to present use. / Alcorn, Jason; Burton, Rob; Topping, Annie.

    In: International Journal of Urological Nursing, Vol. 9, No. 3, 01.11.2015, p. 177-186.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - BCG treatment for bladder cancer, from past to present use

    AU - Alcorn, Jason

    AU - Burton, Rob

    AU - Topping, Annie

    PY - 2015/11/1

    Y1 - 2015/11/1

    N2 - Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) has been in and out of favour. However, only a small proportion of patients, as low as 16%, complete what is seen as a gold standard treatment. To understand why it is the gold standard treatment the epidemiology and aetiology of NMIBC is presented. This article discusses how BCG was first discovered in cows to it being used as a treatment for NMIBC. The issues of side effects which can be from mild to severe and local to systemic, will be discussed. The impact of age in the tolerance of this treatment will be also be looked at. In conclusion, with BCG treatment being the preferred option for NMIBC, it also comes with significant side effects. It is these that should be of concern to the health care professional as they can be potentially life threatening.

    AB - Since the turn of the 20th century Bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer (NMIBC) has been in and out of favour. However, only a small proportion of patients, as low as 16%, complete what is seen as a gold standard treatment. To understand why it is the gold standard treatment the epidemiology and aetiology of NMIBC is presented. This article discusses how BCG was first discovered in cows to it being used as a treatment for NMIBC. The issues of side effects which can be from mild to severe and local to systemic, will be discussed. The impact of age in the tolerance of this treatment will be also be looked at. In conclusion, with BCG treatment being the preferred option for NMIBC, it also comes with significant side effects. It is these that should be of concern to the health care professional as they can be potentially life threatening.

    KW - Bacillus Calmette-Guerin

    KW - Bladder

    KW - Carcinoma

    KW - Immunotherapy

    KW - Intravesical therapy

    KW - Non-muscle-invasive bladder cancer

    UR - http://www.scopus.com/inward/record.url?scp=84944451804&partnerID=8YFLogxK

    U2 - 10.1111/ijun.12064

    DO - 10.1111/ijun.12064

    M3 - Article

    VL - 9

    SP - 177

    EP - 186

    JO - International Journal of Urological Nursing

    T2 - International Journal of Urological Nursing

    JF - International Journal of Urological Nursing

    SN - 1749-7701

    IS - 3

    ER -